211 related articles for article (PubMed ID: 33537466)
1. High-dose rate brachytherapy in localized penile cancer: 5-Year clinical outcome analysis.
Martz N; Bodokh Y; Gautier M; Thamphya B; Schiappa R; Lam Cham Kee D; Chevallier D; Hannoun A; Chand ME; Hannoun-Levi JM
Clin Transl Radiat Oncol; 2021 Mar; 27():89-95. PubMed ID: 33537466
[TBL] [Abstract][Full Text] [Related]
2. Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial.
Hannoun-Levi JM; Chand-Fouche ME; Pace-Loscos T; Gautier M; Gal J; Schiappa R; Pujol N
Clin Transl Radiat Oncol; 2022 Nov; 37():64-70. PubMed ID: 36093342
[TBL] [Abstract][Full Text] [Related]
3. High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort.
Marotte D; Gal J; Schiappa R; Gautier M; Boulahssass R; Chand-Fouche ME; Hannoun-Levi JM
Clin Transl Radiat Oncol; 2022 Jul; 35():104-109. PubMed ID: 35692263
[TBL] [Abstract][Full Text] [Related]
4. High-dose-rate brachytherapy boost for locally advanced cervical cancer: Oncological outcome and toxicity analysis of 4 fractionation schemes.
le Guyader M; Lam Cham Kee D; Thamphya B; Schiappa R; Gautier M; Chand-Fouche ME; Hannoun-Levi JM
Clin Transl Radiat Oncol; 2022 Jan; 32():15-23. PubMed ID: 34816022
[TBL] [Abstract][Full Text] [Related]
5. 10-Year oncological outcome report after second conservative treatment for ipsilateral breast tumor event.
Hannoun-Levi JM; Gal J; Schiappa R; Chand ME
Clin Transl Radiat Oncol; 2023 Jan; 38():71-76. PubMed ID: 36388247
[TBL] [Abstract][Full Text] [Related]
6. High-dose rate brachytherapy in localized penile cancer: short-term clinical outcome analysis.
Rouscoff Y; Falk AT; Durand M; Gal J; Chand ME; Gautier M; Marsaud A; Chevallier D; Amiel J; Hannoun-Levi JM
Radiat Oncol; 2014 Jun; 9():142. PubMed ID: 24941956
[TBL] [Abstract][Full Text] [Related]
7. American Brachytherapy Society-Groupe Européen de Curiethérapie-European Society of Therapeutic Radiation Oncology (ABS-GEC-ESTRO) consensus statement for penile brachytherapy.
Crook JM; Haie-Meder C; Demanes DJ; Mazeron JJ; Martinez AA; Rivard MJ
Brachytherapy; 2013; 12(3):191-8. PubMed ID: 23453681
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerance of high-dose-rate brachytherapy boost after external radiotherapy in the treatment of squamous cell carcinoma of the anal canal.
Bertin E; Benezery K; Kee DLC; François E; Evesque L; Gautier M; Gerard JP; Hannoun-Levi JM; Falk AT
J Contemp Brachytherapy; 2018 Dec; 10(6):522-531. PubMed ID: 30662475
[TBL] [Abstract][Full Text] [Related]
9.
Hannoun-Levi JM; Chamorey E; Boulahssass R; Polgar C; Strnad V;
Clin Transl Radiat Oncol; 2021 Jul; 29():1-8. PubMed ID: 33997321
[TBL] [Abstract][Full Text] [Related]
10. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
11. Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept.
Fokdal L; Tanderup K; Nielsen SK; Christensen HK; Røhl L; Pedersen EM; Schønemann NK; Lindegaard JC
Radiother Oncol; 2011 Sep; 100(3):473-9. PubMed ID: 21924784
[TBL] [Abstract][Full Text] [Related]
12. Second Conservative Treatment for Local Recurrence Breast Cancer: A GEC-ESTRO Oncological Outcome and Prognostic Factor Analysis.
Hannoun-Levi JM; Gal J; Polgar C; Strnad V; Loessl K; Polat B; Kauer-Domer D; Schiappa R; Gutierrez C
Int J Radiat Oncol Biol Phys; 2023 Dec; 117(5):1200-1210. PubMed ID: 37459998
[TBL] [Abstract][Full Text] [Related]
13. Salvage Low Dose Rate Brachytherapy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes.
Barbera F; Triggiani L; Buglione M; Ghirardelli P; Vitali P; Caraffini B; Borghetti P; Greco D; Bardoscia L; Pasinetti N; Costa L; Maddalo M; Ghedi B; La Face B; Magrini SM
Clin Med Insights Oncol; 2017; 11():1179554917738765. PubMed ID: 29151782
[TBL] [Abstract][Full Text] [Related]
14. High-dose-rate brachytherapy for localized penile cancer: Evolution of a technique.
Marbán M; Crook J; Keyes M; Dubash R; Batchelar D
Brachytherapy; 2020; 19(2):201-209. PubMed ID: 31959520
[TBL] [Abstract][Full Text] [Related]
15. Reporting and validation of gynaecological Groupe Euopeen de Curietherapie European Society for Therapeutic Radiology and Oncology (ESTRO) brachytherapy recommendations for MR image-based dose volume parameters and clinical outcome with high dose-rate brachytherapy in cervical cancers: a single-institution initial experience.
Mahantshetty U; Swamidas J; Khanna N; Engineer R; Merchant NH; Deshpande DD; Shrivastava S
Int J Gynecol Cancer; 2011 Aug; 21(6):1110-6. PubMed ID: 21633296
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy for penile cancers.
Escande A; Peiffert D; Dejean C; Hannoun-Lévi JM; Cordoba A; Pommier P; Haie-Méder C; Chargari C
Cancer Radiother; 2022; 26(1-2):323-328. PubMed ID: 34953715
[TBL] [Abstract][Full Text] [Related]
17. Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients).
Cordoba A; Escande A; Lopez S; Mortier L; Mirabel X; Coche-Déqueant B; Lartigau E
Radiat Oncol; 2016 Jul; 11():96. PubMed ID: 27464910
[TBL] [Abstract][Full Text] [Related]
18. Salvage brachytherapy for second ipsilateral breast tumor event: Relating dosimetric analysis to late side effects.
Abdul-Latif M; Gal J; Schiappa R; Rizzi Y; Gautier M; Hannoun-Levi JM
Brachytherapy; 2024; 23(3):335-341. PubMed ID: 38383205
[TBL] [Abstract][Full Text] [Related]
19. Long term experience with 3D image guided brachytherapy and clinical outcome in cervical cancer patients.
Ribeiro I; Janssen H; De Brabandere M; Nulens A; De Bal D; Vergote I; Van Limbergen E
Radiother Oncol; 2016 Sep; 120(3):447-454. PubMed ID: 27157510
[TBL] [Abstract][Full Text] [Related]
20. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
